Richard Hairston, MD
Ophthalmology · Largo, FLNPI 1871591065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $839 and has fallen 63.3% since, to $308 in 2025.
Across 92 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$603
- AbbVie$573
- Regeneron Healthcare Solutions, Inc.$461
- Genentech USA, Inc.$303
- Astellas Pharma US Inc$117
- Eyepoint US, Inc.$95
- plus $477 from 16 others
Across 64 payments — averaging $2243.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$134K
- Bayer$10K
What the payments were for
- Travel & lodging$1937%
- Food & beverage$2,43693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $603 |
| AbbVie(2 entities) | 24 | $573 |
| Regeneron Healthcare Solutions, Inc. | 15 | $461 |
| Genentech USA, Inc. | 14 | $303 |
| Astellas Pharma US Inc | 4 | $117 |
| Eyepoint US, Inc. | 1 | $95 |
| Glaukos Corporation | 2 | $54 |
| Harrow Eye, LLC | 2 | $51 |
| Bausch & Lomb Americas Inc. | 3 | $51 |
| Novartis | 3 | $48 |
| Alimera Sciences, Inc. | 2 | $33 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
| Biogen | 1 | $24 |
| Regeneron | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Sight Sciences, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,628 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 78 | $28,044 |
| Loteprednol Etabonate | 101 | $20,434 |
| LumiganBimatoprost | 54 | $18,990 |
| IlevroNepafenac | 18 | $10,653 |
| RhopressaNetarsudil Mesylate | 13 | $8,795 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $8,007 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 46 | $7,009 |
| Lotemax SmLoteprednol Etabonate | 23 | $6,688 |
| Prednisolone Acetate | 88 | $4,157 |
| Difluprednate | 17 | $3,323 |
| Latanoprost | 105 | $1,719 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 109 | $1,322 |
| Timolol Maleate | 64 | $734 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $506 |
| Dorzolamide Hcl | 15 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $15 | $55,166202 claims |
| AbbVieLumigan, Combigan | $573 | $26,99774 claims |
| NovartisIlevro | $48 | $10,65318 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $19 | $8,79513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Largo
- Neel DesaiLargo$1M
- Robert WeinstockLargo$605K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.